Orna Mor

Title: Orna Mor: Innovator in Oligoribonucleotide Research

Introduction

Orna Mor is a prominent inventor based in Kiryat Ono, Israel. She has made significant contributions to the field of biotechnology, particularly in the development of oligoribonucleotides for therapeutic applications. With a total of 4 patents to her name, her work focuses on innovative solutions for treating fibrotic conditions and other diseases.

Latest Patents

One of Orna Mor's latest patents involves the use of oligoribonucleotides for the treatment of fibrotic diseases. This invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of the human TGaseII gene at the post-transcriptional level. The patent also describes a pharmaceutical composition that includes this compound or a vector capable of expressing the oligoribonucleotide, along with a pharmaceutically acceptable carrier. The invention outlines a method for treating patients suffering from fibrotic diseases such as pulmonary, kidney, and liver fibrosis, as well as ocular scarring. Additionally, it contemplates the use of antibodies to TGaseII polypeptide for treating fibrotic and other diseases.

Career Highlights

Orna Mor has worked with notable companies in the biotechnology sector, including Quark Biotech, Inc. and Quark Pharmaceuticals, Inc. Her experience in these organizations has contributed to her expertise in the development of innovative therapeutic solutions.

Collaborations

Orna has collaborated with several professionals in her field, including Elena Feinstein and Rami Skaliter. These collaborations have further enhanced her research and development efforts in biotechnology.

Conclusion

Orna Mor's contributions to the field of oligoribonucleotide research demonstrate her commitment to advancing medical science. Her innovative patents and collaborations highlight her role as a key figure in the development of treatments for fibrotic conditions and other diseases.